Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. / Petersen, Gitte L; Finnerup, Nanna B; Grosen, Kasper; Pilegaard, Hans K; Tracey, Irene; Benedetti, Fabrizio; Price, Donald D; Jensen, Troels S; Vase, Lene.

I: Pain, Bind 155, Nr. 12, 2014, s. 2687-2698.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Petersen, Gitte L ; Finnerup, Nanna B ; Grosen, Kasper ; Pilegaard, Hans K ; Tracey, Irene ; Benedetti, Fabrizio ; Price, Donald D ; Jensen, Troels S ; Vase, Lene. / Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. I: Pain. 2014 ; Bind 155, Nr. 12. s. 2687-2698.

Bibtex

@article{905f4736d7c94f55979c67e3b3fd1c1a,
title = "Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions",
abstract = "Research on placebo analgesia and nocebo hyperalgesia has primarily included healthy subjects or acute pain patients, and it is unknown whether these effects can be obtained in ongoing pain in patients with chronic pain caused by an identifiable nerve injury. Eighteen patients with post-thoracotomy neuropathic pain were exposed to placebo and nocebo manipulations, in which they received open and hidden administrations of pain-relieving (lidocaine) or pain-inducing (capsaicin) treatment controlled for the natural history of pain. Immediately after the open administration, patients rated their expected pain levels on a mechanical visual analogue scale (M-VAS). They also reported their emotional feelings via a quantitative/qualitative experiential method. Subsequently, patients rated their ongoing pain levels on the M-VAS and underwent quantitative sensory testing (QST) of evoked pain (brush, pinprick, area of hyperalgesia, wind-up-like pain). There was a significant placebo effect on both ongoing (P = 0.009-0.019) and evoked neuropathic pain (P = 0.0005-0.053). Expected pain levels accounted for significant amounts of the variance in ongoing (53.4{\%}) and evoked pain (up to 34.5{\%}) following the open lidocaine administration. Furthermore, patients reported high levels of positive and low levels of negative emotional feelings in the placebo condition compared with the nocebo condition (P ⩽ 0.001). Pain increases during nocebo were non-significant (P = 0.394-1.000). This is the first study to demonstrate placebo effects in ongoing neuropathic pain. It provides further evidence for placebo-induced reduction in hyperalgesia and suggests that patients' expectations co-exist with emotional feelings about treatments.",
author = "Petersen, {Gitte L} and Finnerup, {Nanna B} and Kasper Grosen and Pilegaard, {Hans K} and Irene Tracey and Fabrizio Benedetti and Price, {Donald D} and Jensen, {Troels S} and Lene Vase",
note = "Epub 2 Oct 2014.",
year = "2014",
doi = "10.1016/j.pain.2014.09.036",
language = "English",
volume = "155",
pages = "2687--2698",
journal = "Pain",
issn = "0304-3959",
publisher = "IASP Press",
number = "12",

}

RIS

TY - JOUR

T1 - Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions

AU - Petersen, Gitte L

AU - Finnerup, Nanna B

AU - Grosen, Kasper

AU - Pilegaard, Hans K

AU - Tracey, Irene

AU - Benedetti, Fabrizio

AU - Price, Donald D

AU - Jensen, Troels S

AU - Vase, Lene

N1 - Epub 2 Oct 2014.

PY - 2014

Y1 - 2014

N2 - Research on placebo analgesia and nocebo hyperalgesia has primarily included healthy subjects or acute pain patients, and it is unknown whether these effects can be obtained in ongoing pain in patients with chronic pain caused by an identifiable nerve injury. Eighteen patients with post-thoracotomy neuropathic pain were exposed to placebo and nocebo manipulations, in which they received open and hidden administrations of pain-relieving (lidocaine) or pain-inducing (capsaicin) treatment controlled for the natural history of pain. Immediately after the open administration, patients rated their expected pain levels on a mechanical visual analogue scale (M-VAS). They also reported their emotional feelings via a quantitative/qualitative experiential method. Subsequently, patients rated their ongoing pain levels on the M-VAS and underwent quantitative sensory testing (QST) of evoked pain (brush, pinprick, area of hyperalgesia, wind-up-like pain). There was a significant placebo effect on both ongoing (P = 0.009-0.019) and evoked neuropathic pain (P = 0.0005-0.053). Expected pain levels accounted for significant amounts of the variance in ongoing (53.4%) and evoked pain (up to 34.5%) following the open lidocaine administration. Furthermore, patients reported high levels of positive and low levels of negative emotional feelings in the placebo condition compared with the nocebo condition (P ⩽ 0.001). Pain increases during nocebo were non-significant (P = 0.394-1.000). This is the first study to demonstrate placebo effects in ongoing neuropathic pain. It provides further evidence for placebo-induced reduction in hyperalgesia and suggests that patients' expectations co-exist with emotional feelings about treatments.

AB - Research on placebo analgesia and nocebo hyperalgesia has primarily included healthy subjects or acute pain patients, and it is unknown whether these effects can be obtained in ongoing pain in patients with chronic pain caused by an identifiable nerve injury. Eighteen patients with post-thoracotomy neuropathic pain were exposed to placebo and nocebo manipulations, in which they received open and hidden administrations of pain-relieving (lidocaine) or pain-inducing (capsaicin) treatment controlled for the natural history of pain. Immediately after the open administration, patients rated their expected pain levels on a mechanical visual analogue scale (M-VAS). They also reported their emotional feelings via a quantitative/qualitative experiential method. Subsequently, patients rated their ongoing pain levels on the M-VAS and underwent quantitative sensory testing (QST) of evoked pain (brush, pinprick, area of hyperalgesia, wind-up-like pain). There was a significant placebo effect on both ongoing (P = 0.009-0.019) and evoked neuropathic pain (P = 0.0005-0.053). Expected pain levels accounted for significant amounts of the variance in ongoing (53.4%) and evoked pain (up to 34.5%) following the open lidocaine administration. Furthermore, patients reported high levels of positive and low levels of negative emotional feelings in the placebo condition compared with the nocebo condition (P ⩽ 0.001). Pain increases during nocebo were non-significant (P = 0.394-1.000). This is the first study to demonstrate placebo effects in ongoing neuropathic pain. It provides further evidence for placebo-induced reduction in hyperalgesia and suggests that patients' expectations co-exist with emotional feelings about treatments.

U2 - 10.1016/j.pain.2014.09.036

DO - 10.1016/j.pain.2014.09.036

M3 - Journal article

VL - 155

SP - 2687

EP - 2698

JO - Pain

JF - Pain

SN - 0304-3959

IS - 12

ER -